Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Pancreatic Neoplasms 151Breast Neoplasms 116Carcinoma, Non-Small-Cell Lung 65Triple Negative Breast Neoplasms 45Neoplasms 44Neoplasm Metastasis 44Lung Neoplasms 26Ovarian Neoplasms 25Squamous Cell Carcinoma of Head and Neck 24Stomach Neoplasms 22Melanoma 16Esophageal Neoplasms 16Adenocarcinoma 15Head and Neck Neoplasms 13Recurrence 12Esophageal Squamous Cell Carcinoma 12Cholangiocarcinoma 12Sarcoma 11Parkinson Disease 4, Autosomal Dominant Lewy Body 11Small Cell Lung Carcinoma 10Fallopian Tube Neoplasms 10Uterine Cervical Neoplasms 9Urinary Bladder Neoplasms 8Pancreatic Adenocarcinoma 8Colorectal Neoplasms 8Prostatic Neoplasms 7Inflammatory Breast Neoplasms 7Carcinoma, Pancreatic Ductal 7Breast Neoplasms, Male 7Biliary Tract Neoplasms 7

Interventions

Cisplatin 4sintilimab 1Radiation Dose Hypofractionation 1Radiation 1Irinotecan 1Immunotherapy 1Brachytherapy 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Locally Advanced Cervical Carcinoma × Albumin-Bound Paclitaxel × Clear all
NCT06391190 2024-04-30

Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer

RenJi Hospital

Phase 1/2 Recruiting
20 enrolled
Gynecologic

Locally Advanced Cervical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡